Treatment of hypertension in daily practice. Current results of a postmarketing surveillance study with telmisartan;Die therapie der hypertonie in der täglichen praxis. Aktuelle ergebnisse einer postmarketing-surveillance-studie mit telmisartan

MMW-Fortschritte der Medizin

Volumn 149, Issue 27-28 SUPPL., 2007, Pages 59-67

  Klocke, R K ^a,b   Landen, H ^b  

^a Bayer Vital GmbH ^*

^b St Marienhospital Vechta   (Germany)

Author keywords

Diastolic blood pressure; Hydrochlorothiazide; Pulse pressure; Systolic blood pressure; Telmisartan

Indexed keywords

HYDROCHLOROTHIAZIDE; TELMISARTAN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTMARKETING SURVEILLANCE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DRUG THERAPY, COMBINATION; FAMILY PRACTICE; FEMALE; GERMANY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES;

EID: 34547197324     PISSN: 14383276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Assmann, G., Cullen, P., Evers, T., et al.: Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur. Heart J. 20 (2005), 2120-2126.
2. Bakris, G.: Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. J. Clin. Hypertens. 4 (2002), (Suppl. 1), 26-31.
3. Battershill, A. J., Scott, L. J.: Telmisartan. A Review of its Use in the Management of Hypertension. Drugs 66 (2006), 51-83.
4. Böger, R. H., Benndorf, R. A., Appel, D., et al.: Mit dem Blutdruck zugleich metabolische Parameter bessern. Herz 31 (2006), (Suppl.), 18-19.
5. Derosa, G., Ragonesi, P. D., Mugellini, A., et al.: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized double-blind, placebo-controlled 12-month study. Hypertens. Res. 27 (2004), 457-464.
6. ESH/ESC Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21 (2003), 1011-1053.
7. Franklin, S. S., Gustin, W., Wong, N. D., et al.: Hemodynamic patterns of age-related changes in blood. The Framingham Heart Study. Circulation 96 (1997), 308-315.
8. Gasse, C., Hense, H, Stieber, J., et al.: Assessing hypertension management in the community - Trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project Augsburg 1984-1995. J. Hum. Hypertens. 15 (2001), 27-36.
9. Mallion, J., Siche, J., Lacourcière, Y.: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J. Hum. Hypertens. 13 (1999), 657-664.
10. Michel, M. C., Bohner, H., Köster, J, et al.: Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf. 27 (2004), 335-344.
11. Muller, J. E., Stone, P., H., Turi, Z., G., et al.: Circadian variation in the frequency of onset of acute myocardial infarction. N. Engl. J. Med. 313 (1985), 1315-1322.
12. Scholze J., Müller U.: Blutdrucksenkung und Risikoreduktion unter der Therapie mit Valsartan und seinen Fixkombinationen mit HCT. MMW Fortschr. Med. 2006; 148 (Orig.) (3): 139-145.
13. Vital, C., Mercuro, G., Castiglioni, C., et al.: Metabolic effect of Telmisartan and Losartan in hypertensive patients with metabolic syndrome. Cardivascular Diabetology 4 (2005), 6.
14. White, W. B., Lacourcière, Y., Davidai, G.: Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am. J. Hypertens. 17 (2004), 347-353.
15. WHO/ISH-Guidelines-Subcommittee: 1999 World Health Organization- international Society Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens. 17 (1999), 151-183.
16. Zhu, J. R., Bai, J., Cai, N. S., et al.: Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int. J. Clin. Pract. 58 (2004), (Suppl. 145), 46-49.